Biocorrx Inc. (BICX) — SEC Filings
Biocorrx Inc. (BICX) — 13 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 6 10-Q, 5 8-K, 2 10-K.
View Biocorrx Inc. on SEC EDGAR
Overview
Biocorrx Inc. (BICX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: BioCorRx Inc. reported a significant increase in revenue to $948,362 for the nine months ended September 30, 2025, compared to $7,665 in the same period of 2024, primarily driven by the acquisition of Lucemyra assets. Despite this revenue growth, the company's net loss attributable to BioCorRx Inc.
Sentiment Summary
Across 13 filings, the sentiment breakdown is: 1 bearish, 10 neutral, 2 mixed. The dominant filing sentiment for Biocorrx Inc. is neutral.
Filing Type Overview
Biocorrx Inc. (BICX) has filed 6 10-Q, 5 8-K, 2 10-K with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (13)
Risk Profile
Risk Assessment: Of BICX's 12 recent filings, 3 were flagged as high-risk, 7 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $948,362 |
| Net Income | $(3,992,701) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $287,688 |
| Operating Margin | N/A |
| Total Assets | $7,533,473 |
| Total Debt | $20,297,768 |
Key Executives
- Louis Lucido
- Dr. David R. Smith
- Mr. Robert L. Johnson
- Mr. Michael L. Smith
Industry Context
BioCorRx operates in the pharmaceutical sector, specifically focusing on addiction treatment. The market is competitive, with established players and emerging therapies. The company's strategy involves leveraging an acquired FDA-approved product (Lucemyra) while developing its own pipeline of naltrexone-based treatments.
Top Tags
financials (4) · 10-Q (3) · Biotechnology (2) · Pharmaceuticals (2) · SEC Filing (2) · material-agreement (2) · equity-sale (2) · 10-K (2) · BioCorRx (2) · Financial Report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $948,362 | Increased from $7,665 in 2024 for the nine months ended September 30, 2025, primarily due to Lucemyra acquisition. |
| Net Loss Attributable to BioCorRx Inc. | $(3,992,701) | Widened from $(3,941,509) in 2024 for the nine months ended September 30, 2025. |
| Total Assets | $7,533,473 | Increased significantly from $385,941 at December 31, 2024, largely due to acquisition-related intangible assets and goodwill. |
| Total Liabilities | $20,297,768 | Increased from $12,741,173 at December 31, 2024, indicating growing financial obligations. |
| Cash and Cash Equivalents | $287,688 | Increased from $88,033 at December 31, 2024, but remains low relative to liabilities. |
| Intangible Assets, net | $3,011,833 | Significant increase from $7,848 at December 31, 2024, primarily from the Lucemyra acquisition. |
| Goodwill | $2,840,400 | Newly recognized asset from the Lucemyra acquisition as of September 30, 2025. |
| Accumulated Deficit | $(87,201,843) | Continued to grow from $(83,209,142) at December 31, 2024, reflecting ongoing losses. |
| Research and Development Expenses | $1,463,439 | Increased from $1,210,334 in 2024 for the nine months ended September 30, 2025. |
| Selling, General and Administrative Expenses | $3,254,760 | Increased from $2,773,288 in 2024 for the nine months ended September 30, 2025. |
| Revenues, net | $313,137 | for the six months ended June 30, 2025, up from $7,665 in 2024 |
| Net loss attributable to BioCorRx Inc. | $2,074,825 | for the six months ended June 30, 2025, narrowed from $2,454,122 in 2024 |
| Total liabilities | $19,694,108 | as of June 30, 2025, increased from $12,741,173 at December 31, 2024 |
| Accumulated deficit | $85,283,967 | as of June 30, 2025, increased from $83,209,142 at December 31, 2024 |
| Cash | $111,872 | as of June 30, 2025, up from $88,033 at December 31, 2024 |
Frequently Asked Questions
What are the latest SEC filings for Biocorrx Inc. (BICX)?
Biocorrx Inc. has 13 recent SEC filings from Jan 2024 to Nov 2025, including 6 10-Q, 5 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BICX filings?
Across 13 filings, the sentiment breakdown is: 1 bearish, 10 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Biocorrx Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Biocorrx Inc. (BICX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Biocorrx Inc.?
Key financial highlights from Biocorrx Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BICX?
The investment thesis for BICX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Biocorrx Inc.?
Key executives identified across Biocorrx Inc.'s filings include Louis Lucido, Dr. David R. Smith, Mr. Robert L. Johnson, Mr. Michael L. Smith.
What are the main risk factors for Biocorrx Inc. stock?
Of BICX's 12 assessed filings, 3 were flagged high-risk, 7 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Biocorrx Inc.?
Forward guidance and predictions for Biocorrx Inc. are extracted from SEC filings as they are enriched.